FBT vs. KNOS, SGE, DARK, SCT, SXS, CCC, RSW, NETW, OXIG, and BYIT
Should you be buying First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? The main competitors of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Kainos Group (KNOS), The Sage Group (SGE), Darktrace (DARK), Softcat (SCT), Spectris (SXS), Computacenter (CCC), Renishaw (RSW), Network International (NETW), Oxford Instruments (OXIG), and Bytes Technology Group (BYIT). These companies are all part of the "computer and technology" sector.
Kainos Group (LON:KNOS) and First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.
Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.
Kainos Group has a net margin of 12.74% compared to Kainos Group's net margin of 0.00%. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity of 34.05% beat Kainos Group's return on equity.
Kainos Group received 170 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. Likewise, 72.02% of users gave Kainos Group an outperform vote while only 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote.
In the previous week, Kainos Group had 4 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 4 mentions for Kainos Group and 0 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 0.35 beat Kainos Group's score of 0.00 indicating that Kainos Group is being referred to more favorably in the media.
Kainos Group currently has a consensus target price of GBX 1,198.75, suggesting a potential upside of 1.42%. Given First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's higher possible upside, research analysts clearly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.
46.3% of Kainos Group shares are held by institutional investors. 37.5% of Kainos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 14 of the 15 factors compared between the two stocks.
Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List
Related Companies and Tools
